글로벌 하시모토 갑상선염 약물 시장 – 2030년까지의 산업 동향 및 예측

 하시모토 갑상선염 약물 시장 분석 및 규모

최근 몇 년 동안 하시모토병 시장은 2023년에서 2030년의 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 세계보건기구(WHO)에 따르면 요오드의 권장 일일 섭취량(RDI)은 하루 150mcg로 건강한 모든 사람의 95% 이상에게 충분한 양이며, 임신 및 수유부는 더 많은 양이 필요합니다. 과도한 요오드 섭취 는 이미 하시모토병의 위험이 있는 사람들에게 트리거 역할을 하는 주요 원인입니다. 갑상선 기능 장애의 가족력이 있는 사람들은 하시모토병에 걸릴 가능성이 더 높습니다.                                

Data Bridge Market Research는 2022년에 7,200.00백만 달러였던 글로벌 하시모토 갑상선염 약물 시장이 2030년까지 12,463.74백만 달러에 도달할 것으로 예상되며 2023년에서 2030년까지의 예측 기간 동안 7.10%의 CAGR을 보일 것으로 분석했습니다. "캡슐"은 갑상선 기능 저하증의 유병률이 증가함에 따라 글로벌 하시모토 갑상선염 약물 시장의 제품 유형 세그먼트를 지배하고 있습니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

하시모토 갑상선염 약물 시장 범위 및 세분화

시장 정의

하시모토병은 갑상선에 영향을 미치는 질환입니다. 하시모토병은 만성 림프구성 갑상선염, 하시모토 갑상선염 또는 자가면역성 갑상선염이라고도 합니다. 갑상선은 신체의 거의 모든 대사 활동(음식을 에너지로 전환하는 방식)을 조절하고 유지하는 호르몬을 생성합니다. 하시모토 갑상선염은 면역 체계가 갑상선을 잘못 식별하여 영향을 미치는 자가면역 질환입니다.            

세계 하시모토 갑상선염 약물 시장 동향

운전자

• 갑상선 기능 저하증 유병률 증가

갑상선 기능 저하증의 유병률 증가는 하시모토병 시장의 성장을 촉진할 것으로 추정됩니다. 갑상선이 면역 체계에 의해 손상되면 신체의 필요를 충족시킬 만큼 충분한 갑상선 호르몬을 생산할 수 없어 하시모토 갑상선 기능 저하증이 발생합니다. 갑상선 호르몬은 음식을 에너지로 전환하는 과정인 신진대사를 제어합니다.

• 의료 인프라에 대한 투자 증가

하시모토병 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하려고 하며 이는 시장 역학에 더욱 영향을 미칠 것입니다 .

• 노령 인구의 증가

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2023-2030. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Hashimoto’s disease, further estimated to enhance the market’s growth rate.

• Surging Incidences of Autoimmune Disease

The increasing incidences of autoimmune disease is anticipated to influence the growth of Hashimoto’s disease market. Rheumatoid arthritis, lupus and type 1 diabetes are among the various autoimmune disease that increases the risk of Hashimoto’s disease and further flourish the markets growth. Furthermore, rising initiatives by public and private organizations to spread awareness and family history with thyroid diseases will expand the global Hashimoto’s thyroiditis drug market. In addition, rising radiation exposure and high consumption alcohol and alcohol will result in the expansion of global Hashimoto’s thyroiditis drug market.

 Opportunities

• Increase in the number of Research and Development Activities

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Hashimoto’s disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

• Growing Awareness and Diagnosis

There is a growing awareness among healthcare professionals and the general population regarding thyroid disorders, including Hashimoto's thyroiditis. Improved diagnostic techniques and increased screening efforts have led to earlier detection and diagnosis of the condition. This increased awareness and diagnosis contribute to a larger patient pool and a corresponding market opportunity.

Restraints/Challenges

• Limited Treatment Options

While there are medications available for managing Hashimoto's thyroiditis, there is still a lack of specific drugs that target the underlying autoimmune process. The limited treatment options restrict the market potential and hinder the development of more effective therapies.

• Adverse Effects and Safety Concerns

Some of the existing treatments for Hashimoto's thyroiditis may have side effects or safety concerns. This can lead to hesitancy among patients and healthcare professionals in using certain medications, limiting their adoption and market growth.

This  global  Hashimoto’s thyroiditis drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Hashimoto’s thyroiditis drug market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2023, Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the TEPEZZA label to specify its use for the treatment of “Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration
• In October 2022, PledPharma AB (publ) (STO: PLED) (“PledPharma” or the “Company”) had announced that it had  entered into an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (“RTT” or “Rare Thyroid Therapeutics”), a privately held drug development company with the ultra-orphan asset

Global Hashimoto’s thyroiditis Drug Market Scope

The global Hashimoto’s thyroiditis drug market is segmented on the basis of product type, diagnosis, treatment, route of administration, distribution channel and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Capsule
• Tablet
• Powder

Diagnosis

• Thyroid-Stimulating Hormone Test
• Thyroxine Test
• Antithyroid Antibody Test

Treatment

• Levothyroxine
• Triiodothyronine
• Desiccated Thyroid Extract

Route of Administration

• Oral Intravenous
• Others

Distribution Channel

• Hospital Pharmacies
•  Retail Pharmacies
•  Online Pharmacies

 End User

• Hospitals
• Clinics 
• Medical Laboratories
• Others

 Global Hashimoto’s Thyroiditis Drug Market Regional Analysis/Insights

The global Hashimoto’s thyroiditis drug market is analysed and market size insights and trends are provided by country, product type, diagnosis, treatment, route of administration, distribution channel and end users as referenced above.

The countries covered in the  global  Hashimoto’s thyroiditis drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the global Hashimoto’s thyroiditis drug market because of the strong base of healthcare facilities, strong presence of major players in the market, increases cases of autoimmune thyroid diseases and deficiency of iodine content and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth in the global Hashimoto’s thyroiditis drug market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The  global Hashimoto’s thyroiditis drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global Hashimoto’s thyroiditis drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global Hashimoto’s thyroiditis drug market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Hashimoto’s thyroiditis Drug Market Share Analysis

글로벌 하시모토 갑상선염 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 하시모토 갑상선염 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 하시모토 갑상선염 약물 시장에서 활동하는 주요 기업은 다음과 같습니다.

• GSK plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 아스트라제네카(영국)
• 존슨앤존슨 서비스 주식회사(미국)
• 시플라 주식회사(미국)
• 애벗(미국)
• AbbVie Inc.(미국)
• 머크 KGaA(독일)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• Provell Pharmaceuticals, LLC(미국)
• 알보젠(미국)
• 피라말 엔터프라이즈 유한회사(미국)
• Dr. Reddy's Laboratories Ltd. (인도)
• 파이저 주식회사(미국)
• Fresenius Kabi AG(독일)

SKU-44986